摘要
目的:观察补康灵不同时段联合TP方案(紫杉醇+顺铂联合化疗)治疗非小细胞肺癌(NSCLC)的疗效。方法:120例NSCLC患者随机分为4组,分别为提前7、3d应用补康灵加化疗组(A、B组),补康灵同时加化疗组(C组),单纯化疗组(D组)。化疗2个疗程后评价有效率、化疗期间和化疗后患者毒副作用和生存质量的改善情况。结果:各组对瘤体的近期疗效相似(P>0.05);与D组比较,A组骨髓抑制、疲劳的发生率较低(P<0.05),而B、C组毒副反应发生率有降低趋势(P>0.05);与D组比较,A、B组生存质量有明显提高(P<0.01)。结论:补康灵联合TP方案有增强客观疗效的趋势,可以减轻化疗毒副作用、提高患者生存质量,且先于化疗前7d给药治疗效果较好。
OBJECTIVE： To observe the clinical efficacy of bukangling combined with TP scheme in the treatment of non-small-cell lung cancer （NSCLC） in the different periods. METHODS： 120 NSCLC patients were randomly divided into 4 groups, i.e. group A was applied bukangling in advance for 7 d combined with TP scheme. Group B was applied bukangling in advance for 3 d. Group C was treated with bukangling and TP scheme at the same time, while group D was given pure chemotherapy. Effective rat, side effects and improvement in quality of life during chemotherapy and after chemotherapy were evaluated after 2 courses. RESULTS： The short-term curative effects were similar （P〉0.05）. Compared with group D, the incidence of bone mar- row suppression and fatigue was lower in group A（P〈0.05）, and the risk of adverse drug reaction in group B and C decreased （P〉0.05）. Compared with group D, the quality of life had increased significantly in group A and B （P〈0.01）. CONCLUSION： Bukangling combined with TP scheme in the treatment of NSCLC strengthen the better trend in the objective curative effect, alleviate side effects of chemotherapy, and improve the quality of life of the patients. Bukangling which is given before chemotherapy for 7 d obtain optimal effect.
出处
《中国药房》
CAS
CSCD
2012年第11期1034-1036,共3页
China Pharmacy
基金
江苏省卫生厅医学科技发展基金会临床肿瘤学科研课题(P200939)
关键词
补康灵
紫杉醇
顺铂
联合治疗
非小细胞肺癌
Bukangling
Paclitaxel
Cisplatin
Combined treatment
Non-small-cell lung cancer
作者简介
副主任药师，硕士。研究方向：医院药学。电话：0513-86729461。E—mail：ntzj10513@163．com
